Q-omics provides the consensus-scored DIPK1A profile across patient tissues and cancer cell-line models. DIPK1A expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, DIPK1A is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, DIPK1A RNA expression shows 19,254 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRP, HNSC, and THYM as cancer lineages where DIPK1A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DIPK1A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DIPK1A survival associations across molecular data types. DIPK1A RNA expression shows survival associations in the most cancer types (25), followed by mutation status (1) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DIPK1A RNA expression–survival associations across cancer types. High DIPK1A expression shows unfavorable associations in KIRP, HNSC, LIHC and UCEC, but favorable associations in COAD and THCA. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for DIPK1A RNA expression.
This table summarizes DIPK1A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for DIPK1A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DIPK1A shows lower tumor expression in THCA, UCEC and BRCA and higher tumor expression in HNSC, LUAD and LUSC. The HNSC box plot shows higher DIPK1A RNA expression in tumor versus normal tissue (log2 FC = +1.891, t-test p < 0.001).
This table shows molecular features associated with DIPK1A in patient tissues and cancer cell lines. In patient samples, DIPK1A shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, DIPK1A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BONE.
